Moberg Pharma
8.14
SEK
-1.45 %
Less than 1K followers
MOB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-1.45%
-14.76%
-19.96%
-47.42%
-71.58%
-49.44%
-74.91%
-87.02%
-86.38%
Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.
Read moreMarket cap
389.74M SEK
Turnover
1.61M SEK
Revenue
9.81M
EBIT %
-3,311.21 %
P/E
-
Dividend yield-%
-
Financial calendar
13.5
2025
Interim report Q1'25
22.5
2025
General meeting '25
12.8
2025
Interim report Q2'25
ShowingAll content types
Moberg Pharma Year-end report 2024
Moberg Pharma: Terclara (MOB-015) is now being launched in Norway
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools